Company Overview and News
The local stock barometer slipped on Wednesday as foreign funds continued to flow out of local equities in the absence of fresh catalysts.
SVTMF PSKXF GTMEY AYAAY SM GLOPP SECB MRAIF GLO SMIVY SYBJF PHSXY GTMEF PSE GLOPA MRC ALI AYAAF
THE PHILIPPINE STOCK EXCHANGE index (PSEi) exited bear territory on Friday amid what one analyst described as “a dizzying rally”, but its strong recovery was not enough to prevent its third straight week-on-week drop.
FPHPC MPCIY BDOUY AYAAY UVRBY AEV FPHP DD SECB MRAIF BDOUF BDO ABTZY MPI MPCFF SYBJF URC MRC ALI FPH UVRBF AYAAF
The local stock barometer gained on Tuesday as local investors made up for sluggish foreign investor appetite.
SVTMF SMCP1 BDOUY SM MRAIF BDOUF SMGBF SMIVY SMC PHSXY PSE AYAAF PSKXF AYAAY SMGBY BDO SMC2B SMC2A SMC2D IDC SMC2C SMC2F SMC2E ALI MRC
MRC Allied, Inc. may choose to participate only in the power plant component of the liquefied natural gas (LNG) facility it is studying to build, its top official said.
STOCKS opened the second quarter on a positive note, trekking higher on the back of positive economic data from the United States amid thinner trading. The 30-member Philippine Stock Exchange index rose 0.75% or 59.62 points to finish at 8,039.45 on Monday, April 2. The broader all-shares index likewise climbed 0.6% or 28.99 points to 4,869.55. “It was up after the economic data coming out from the US on consumer spending.
SMIVY PSKXF SVTMF NOW PHSXY SM PSE DNOW MRC MRAIF
The local stock market officially entered the correction phase on Tuesday, with the index losing over 10 percent of its value from the recent peak, as an overnight bloodbath in Wall Street unnerved investors.
SVTMF PSKXF BDOUY AYAAY SM MRAIF BDOUF BDO SMIVY PHSXY PSE ALI MRC AYAAF
SUNRAY Power, Inc. (SPI) has received its solar service contract from the Energy department, paving the way for the development of its P8.5-billion, 100-megawatt (MW) solar farm in Capas and Bamban in Tarlac province, it said on Tuesday.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:MRC / MRC Allied, Inc. on message board site Silicon Investor.